Seiko Hirono
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seiko Hirono has a total of 354 co-authors. Here are the top co-authors by number of shared publications:
- Manabu Kawai
Second Department of Surgery Wakayama Medical University Wakayama Japan
42 shared publications - Ken-Ichi Okada
Second Department of Surgery, Wakayama Medical University, Wakayama, Japan
29 shared publications - Hiroki Yamaue
Second Department of Surgery, Wakayama Medical University, Wakayama, Japan
28 shared publications Motoki Miyazawa
Second Department of Surgery, School of Medicine, Wakayama Medical University, Japan
28 shared publicationsYuji Kitahata
Second Department of Surgery, School of Medicine, Wakayama Medical University, Japan
25 shared publications- Hiroki Yamaue
Second Department of Surgery, Wakayama Medical University, Wakayama, Japan
20 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Wiley in Annals of Gastroenterological Surgery
The Japanese Hernia Society (JHS) Guidelines for Adult Groin Hernia Management 2024
Groin hernia is a common surgical condition. The Japanese Hernia Society (JHS) Guidelines for Groin Hernia Management 2024 were developed to reflect both international evidence and the realities of clinical practice in Japan. This article is an authorized English translation of a summary of the adult section of the JHS Guidelines for Groin Hernia Management 2024, presenting key clinical questions, recommendations, and concise explanations for an international readership. It covers diagnosis, classification, surgical indications, operative approaches, mesh and fixation, anesthesia, chronic postoperative inguinal pain, recurrent and emergency hernia, training, cost‐effectiveness, and registry‐based outcome assessment; relevant differences from the international HerniaSurge guidelines are discussed. Laparoscopic repair is favored in selected patients when performed by experienced surgeons, particularly for pain reduction and early recovery, whereas open anterior mesh repair remains appropriate when general anesthesia or laparoscopy is unsuitable. For femoral hernia, chronic pain management, recurrent hernia, and incarcerated or strangulated hernia, evidence remains limited, leading to cautious or conditional recommendations.
- 4 November 2026
- Published by Wiley in Annals of Gastroenterological Surgery
Open AccessThe Japanese Hernia Society (JHS) Guidelines for Adult Groin Hernia Management 2024
Groin hernia is a common surgical condition. The Japanese Hernia Society (JHS) Guidelines for Groin Hernia Management 2024 were developed to reflect both international evidence and the realities of clinical practice in Japan. This article is an authorized English translation of a summary of the adult section of the JHS Guidelines for Groin Hernia Management 2024, presenting key clinical questions, recommendations, and concise explanations for an international readership. It covers diagnosis, classification, surgical indications, operative approaches, mesh and fixation, anesthesia, chronic postoperative inguinal pain, recurrent and emergency hernia, training, cost‐effectiveness, and registry‐based outcome assessment; relevant differences from the international HerniaSurge guidelines are discussed. Laparoscopic repair is favored in selected patients when performed by experienced surgeons, particularly for pain reduction and early recovery, whereas open anterior mesh repair remains appropriate when general anesthesia or laparoscopy is unsuitable. For femoral hernia, chronic pain management, recurrent hernia, and incarcerated or strangulated hernia, evidence remains limited, leading to cautious or conditional recommendations.
- Open Access
- 7 August 2025
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 283 (4) , 581-592
Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial)
Objective: This multicenter randomized controlled trial investigated whether the mesenteric approach, which is an infracolic superior mesenteric artery (SMA)-first approach during pancreatoduodenectomy (PD), can improve survival in patients with pancreatic ductal adenocarcinoma (PDAC), compared with the Kocher-first conventional approach. Background: The mesenteric approach might improve surgical outcomes through a nontouch isolation technique for PDAC. Methods: This trial was conducted in 24 Japanese high-volume centers. Patients who were scheduled to undergo PD for resectable PDAC or borderline resectable PDAC with portal vein invasion (BR-PV PDAC) were randomly assigned (1:1) via a central web-based application to the conventional or mesenteric approach. The primary endpoint was overall survival (OS). We also analyzed circulating tumor cell (CTC) DNA in the PV blood obtained during surgery. This trial is registered with ClinicalTrials.gov. NCT03317886, and UMIN Clinical Trials UMIN000029615. Results: Between 2018 and 2021, 360 patients were randomly assigned to conventional (n=181) and mesenteric groups (n=179). With a median follow-up of 39.3 months, the median OS was comparable between conventional and mesenteric groups (41.7 vs. 39.3 months; HR 1.02, 95% CI: 0.76–1.37, P =0.897). CTC analysis showed that the mean change in CTC DNA copy number in PV obtained at laparotomy and just before removal of the specimen was significantly different between the conventional (10.1±2.7) and mesenteric (−7.3±2.6) groups ( P <0.001). Conclusions: The mesenteric approach does not improve survival in patients with resectable or BR-PV PDAC, although it might prevent spread of cancer cells via vessels during surgery through the nontouch isolation procedure.
- 7 August 2025
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 283 (4) , 581-592
Open AccessMesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial)
Objective: This multicenter randomized controlled trial investigated whether the mesenteric approach, which is an infracolic superior mesenteric artery (SMA)-first approach during pancreatoduodenectomy (PD), can improve survival in patients with pancreatic ductal adenocarcinoma (PDAC), compared with the Kocher-first conventional approach. Background: The mesenteric approach might improve surgical outcomes through a nontouch isolation technique for PDAC. Methods: This trial was conducted in 24 Japanese high-volume centers. Patients who were scheduled to undergo PD for resectable PDAC or borderline resectable PDAC with portal vein invasion (BR-PV PDAC) were randomly assigned (1:1) via a central web-based application to the conventional or mesenteric approach. The primary endpoint was overall survival (OS). We also analyzed circulating tumor cell (CTC) DNA in the PV blood obtained during surgery. This trial is registered with ClinicalTrials.gov. NCT03317886, and UMIN Clinical Trials UMIN000029615. Results: Between 2018 and 2021, 360 patients were randomly assigned to conventional (n=181) and mesenteric groups (n=179). With a median follow-up of 39.3 months, the median OS was comparable between conventional and mesenteric groups (41.7 vs. 39.3 months; HR 1.02, 95% CI: 0.76–1.37, P =0.897). CTC analysis showed that the mean change in CTC DNA copy number in PV obtained at laparotomy and just before removal of the specimen was significantly different between the conventional (10.1±2.7) and mesenteric (−7.3±2.6) groups ( P <0.001). Conclusions: The mesenteric approach does not improve survival in patients with resectable or BR-PV PDAC, although it might prevent spread of cancer cells via vessels during surgery through the nontouch isolation procedure.
- Open Access
- 21 April 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 9 (4) , 643-649
Essential Update 2023/2024: Multidisciplinary Treatment for Invasive Intraductal Papillary Mucinous Carcinoma
Invasive intraductal papillary mucinous carcinoma (IPMC) has a high malignant potential, with surgical resection being the only potentially curative treatment. However, even after surgical resection, recurrence occurs frequently and the prognosis is poor once recurrence develops. While retrospective studies aiming to achieve long‐term survival in invasive IPMC patients have been reported, the rarity of invasive IPMC has resulted in small‐scale datasets, leading to low levels of evidence. Consequently, the utility of adjuvant therapy after surgery, neoadjuvant therapy (NAT) before surgery, and treatments for postoperative recurrence in invasive IPMC remains unclear, with treatment strategies varying by institution—ranging from surgical resection alone to approaches based on conventional pancreatic cancer treatment. Recently, several large‐scale multicenter studies on invasive IPMC have been reported. These studies suggested that while adjuvant therapy after surgery may not be beneficial for all invasive IPMC patients, it could potentially extend survival in cases with advanced‐stage disease. Regarding NAT before surgery for invasive IPMC, the number of reported cases is extremely limited, and no definitive evidence has been established. For postoperative recurrence of invasive IPMC, some studies have indicated that administering treatment may prolong survival. Although these large‐scale studies have gradually clarified certain characteristics of invasive IPMC, they are all retrospective in nature, resulting in a low level of evidence. To achieve long‐term survival for invasive IPMC patients, large‐scale prospective multicenter studies are needed in the future.
- 21 April 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 9 (4) , 643-649
Open AccessEssential Update 2023/2024: Multidisciplinary Treatment for Invasive Intraductal Papillary Mucinous Carcinoma
Invasive intraductal papillary mucinous carcinoma (IPMC) has a high malignant potential, with surgical resection being the only potentially curative treatment. However, even after surgical resection, recurrence occurs frequently and the prognosis is poor once recurrence develops. While retrospective studies aiming to achieve long‐term survival in invasive IPMC patients have been reported, the rarity of invasive IPMC has resulted in small‐scale datasets, leading to low levels of evidence. Consequently, the utility of adjuvant therapy after surgery, neoadjuvant therapy (NAT) before surgery, and treatments for postoperative recurrence in invasive IPMC remains unclear, with treatment strategies varying by institution—ranging from surgical resection alone to approaches based on conventional pancreatic cancer treatment. Recently, several large‐scale multicenter studies on invasive IPMC have been reported. These studies suggested that while adjuvant therapy after surgery may not be beneficial for all invasive IPMC patients, it could potentially extend survival in cases with advanced‐stage disease. Regarding NAT before surgery for invasive IPMC, the number of reported cases is extremely limited, and no definitive evidence has been established. For postoperative recurrence of invasive IPMC, some studies have indicated that administering treatment may prolong survival. Although these large‐scale studies have gradually clarified certain characteristics of invasive IPMC, they are all retrospective in nature, resulting in a low level of evidence. To achieve long‐term survival for invasive IPMC patients, large‐scale prospective multicenter studies are needed in the future.
- 15 November 2024
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 48 (10) , 102497
Intra- and inter-patient diversity in hepatocellular carcinoma based on phosphorylation profiles—A pilot study in a single institution
- 15 November 2024
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 48 (10) , 102497
Intra- and inter-patient diversity in hepatocellular carcinoma based on phosphorylation profiles—A pilot study in a single institution
- Open Access
- 17 March 2024
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 8 (5) , 845-859
Is multidisciplinary treatment effective for invasive intraductal papillary mucinous carcinoma?
Background: Surgical resection is standard treatment for invasive intraductal papillary mucinous carcinoma (IPMC); however, impact of multidisciplinary treatment on survival including postoperative adjuvant therapy (AT), neoadjuvant therapy (NAT), and treatment for recurrent lesions is unclear. We investigated the effectiveness of multidisciplinary treatment in prolonging survival of patients with invasive IPMC.Methods: This retrospective multi‐institutional study included 1183 patients with invasive IPMC undergoing surgery at 40 academic institutions. We analyzed the effects of AT, NAT, and treatment for recurrence on survival of patients with invasive IPMC.Results: Completion of the planned postoperative AT for 6 months improved the overall survival (OS), disease‐specific survival (DSS), and recurrence‐free survival (RFS) of patients with stage IIB and stage III resected invasive IPMC, elevated preoperative carbohydrate antigen 19–9 level, lymphovascular invasion, perineural invasion, serosal invasion, and lymph node metastasis on un‐matched and matched analyses. Of the patients with borderline resectable (BR) invasive IPMC, the OS (p = 0.001), DSS (p = 0.001), and RFS (p = 0.001) of patients undergoing NAT was longer than that of those without on the matched analysis. Of the 484 invasive IPMC patients (40.9%) who developed recurrence after surgery, the OS of 365 patients who received any treatment for recurrence was longer than that of those without treatment (40.6 vs. 22.4 months, p < 0.001).Conclusion: Postoperative AT might benefit selected patients with invasive IPMC, especially those at high risk of poor survival. NAT might improve the survivability of BR invasive IPMC. Any treatment for recurrence after surgery for invasive IPMC might improve survival.
- 17 March 2024
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 8 (5) , 845-859
Open AccessIs multidisciplinary treatment effective for invasive intraductal papillary mucinous carcinoma?
Background: Surgical resection is standard treatment for invasive intraductal papillary mucinous carcinoma (IPMC); however, impact of multidisciplinary treatment on survival including postoperative adjuvant therapy (AT), neoadjuvant therapy (NAT), and treatment for recurrent lesions is unclear. We investigated the effectiveness of multidisciplinary treatment in prolonging survival of patients with invasive IPMC.Methods: This retrospective multi‐institutional study included 1183 patients with invasive IPMC undergoing surgery at 40 academic institutions. We analyzed the effects of AT, NAT, and treatment for recurrence on survival of patients with invasive IPMC.Results: Completion of the planned postoperative AT for 6 months improved the overall survival (OS), disease‐specific survival (DSS), and recurrence‐free survival (RFS) of patients with stage IIB and stage III resected invasive IPMC, elevated preoperative carbohydrate antigen 19–9 level, lymphovascular invasion, perineural invasion, serosal invasion, and lymph node metastasis on un‐matched and matched analyses. Of the patients with borderline resectable (BR) invasive IPMC, the OS (p = 0.001), DSS (p = 0.001), and RFS (p = 0.001) of patients undergoing NAT was longer than that of those without on the matched analysis. Of the 484 invasive IPMC patients (40.9%) who developed recurrence after surgery, the OS of 365 patients who received any treatment for recurrence was longer than that of those without treatment (40.6 vs. 22.4 months, p < 0.001).Conclusion: Postoperative AT might benefit selected patients with invasive IPMC, especially those at high risk of poor survival. NAT might improve the survivability of BR invasive IPMC. Any treatment for recurrence after surgery for invasive IPMC might improve survival.
- 12 December 2023
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 31 (3) , 183-192
Is preoperative pancreatic juice cytology useful for determining therapeutic strategies for patients with intraductal papillary mucinous neoplasm of the pancreas?
Background: We compared the results of preoperative pancreatic juice cytology (PJC) and final pathological diagnosis after resection in patients who underwent resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas to determine whether preoperative PJC can help determine therapeutic strategies.Methods: Of 1130 patients who underwent surgical resection IPMN at 11 Japanese tertiary institutions, the study included 852 patients who underwent preoperative PJC guided by endoscopic retrograde cholangiopancreatography (ERCP).Results: The accuracy of preoperative PJC for differentiation between cancerous and noncancerous lesions were 55% for IPMN overall; 59% for the branch duct type; 49% for the main pancreatic duct type; 53% for the mixed type, respectively. On classifying IPMN according to the diameters of the mural nodule (MN) and main pancreatic duct (MPD), the corresponding values for diagnostic performance were 40% for type 1 (MN >= 5 mm and MPD >= 10 mm); 46% for type 2 (MN >= 5 mm and MPD < 10 mm); 61% for type 3 (MN < 5 mm and MPD >= 10 mm); 72% for type 4 (MN < 5 mm and MPD < 10 mm), respectively.Conclusions: PJC in IPMN is not a recommended examination because of its low overall sensitivity and no significant difference in diagnostic performance by type, location, or subclassification. Although the sensitivity is low, the positive predictive value is high, so we suggest that pancreatic juice cytology be performed only in cases where the patient is not sure about surgery.
- 12 December 2023
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 31 (3) , 183-192
Is preoperative pancreatic juice cytology useful for determining therapeutic strategies for patients with intraductal papillary mucinous neoplasm of the pancreas?
Background: We compared the results of preoperative pancreatic juice cytology (PJC) and final pathological diagnosis after resection in patients who underwent resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas to determine whether preoperative PJC can help determine therapeutic strategies.Methods: Of 1130 patients who underwent surgical resection IPMN at 11 Japanese tertiary institutions, the study included 852 patients who underwent preoperative PJC guided by endoscopic retrograde cholangiopancreatography (ERCP).Results: The accuracy of preoperative PJC for differentiation between cancerous and noncancerous lesions were 55% for IPMN overall; 59% for the branch duct type; 49% for the main pancreatic duct type; 53% for the mixed type, respectively. On classifying IPMN according to the diameters of the mural nodule (MN) and main pancreatic duct (MPD), the corresponding values for diagnostic performance were 40% for type 1 (MN >= 5 mm and MPD >= 10 mm); 46% for type 2 (MN >= 5 mm and MPD < 10 mm); 61% for type 3 (MN < 5 mm and MPD >= 10 mm); 72% for type 4 (MN < 5 mm and MPD < 10 mm), respectively.Conclusions: PJC in IPMN is not a recommended examination because of its low overall sensitivity and no significant difference in diagnostic performance by type, location, or subclassification. Although the sensitivity is low, the positive predictive value is high, so we suggest that pancreatic juice cytology be performed only in cases where the patient is not sure about surgery.
- 4 August 2023
- Published by Wiley
- p. 1071-1077
Total Pancreatectomy
- 15 June 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (10) , 106960
Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ductal adenocarcinoma
- 15 June 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (10) , 106960
Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ductal adenocarcinoma
- 8 June 2023
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 27 (1) , S29
Impact of artery-first approach PD on survival
Seiko HIRONO*. Ann Hepatobiliary Pancreat Surg 2023;27:S29. https://doi.org/10.14701/ahbps.2023S1.BP-SY-1-2
- 8 June 2023
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 27 (1) , S29
Impact of artery-first approach PD on survival
Seiko HIRONO*. Ann Hepatobiliary Pancreat Surg 2023;27:S29. https://doi.org/10.14701/ahbps.2023S1.BP-SY-1-2